Delta4

FFG Success Story 🎉: Delta4 joins EU-funded PICKED to advance biomarkers & personalized therapies for CKD. Paul Perco: "EU projects like PICKED build networks & talent." www.ffg.at/success-stor...

Science is stronger when everyone’s voice is heard. At Delta4, we’re committed to creating a space where women can contribute, innovate, and make a lasting impact.

🌐 Learn more about our commitment!
delta4.ai/gender-equal...

#Delta4 #GenderEquality

Solutions for Each Step of Your Pipeline! 🚀

Delta4 combines AI, biology, and drug development expertise to optimize your pipeline from start to finish.

Learn more here!
delta4.ai/development-...

#Delta4 #Pipeline

Just a few days to go!📣

Delta4 will be at BIO-Europe 2025 in Vienna, Nov 3–5.
Meet our CSO, Dr. Klaus Kratochwill, and discover how our Hyper-C platform can help unlock new therapeutic opportunities.

📩 DM us to schedule a meeting at the conference!

👻 This Halloween, we’re shining a light on the eerie side of drug development, highlighting the unseen challenges: from ghost targets to haunted orphan diseases. At Delta4, we turn the spooky into science, uncovering real therapeutic opportunities hidden beneath the (sometimes misleading) surface.

🧬October 26th is #Amyloidosis Day🧬

🔍 At the molecular level, amyloidosis represents a convergence of protein misfolding, proteostasis imbalance, and chronic inflammation. Our Hyper-C platform is modeling diseases as dynamic molecular networks to find new solutions for such complex diseases.

Delta4 hosted a Bioinformatics & -statistics Workshop in Vienna, bringing together PhD students to elevate their CKD research. Learn more: delta4.ai/personalized...

#Delta4 #PICKEDProject

Rare diseases may be complex, but every patient deserves hope, answers, and action.

At Delta4, we harness the power of AI-supported drug repurposing to accelerate breakthroughs and bring new possibilities to those who need them most.
Together, we can change the future of rare disease care.

#Delta4

🧬 At Delta4, we turn omics data into actionable insights. By integrating multi-omics layers into our Hyper-C platform, we simulate disease mechanisms, predict drug responses, and uncover new indications — advancing precision drug repositioning for complex and rare diseases.
#AIinBiotech

Delta4 at BIO-Europe 2025 | Vienna
Looking to expand indications, identify new targets, or discover innovative drug combinations? Meet our CSO and explore how we can unlock new therapeutic opportunities with the help of our platform, Hyper-C.

📩 DM us to schedule a meeting at the conference!

🌍 Living with a rare or chronic disease affects more than the body, it deeply impacts mental health. On #WorldMentalHealthDay, we at Delta4 stand with patients and families, driving innovation in drug repurposing to ease both physical and emotional burdens. 💚 #MentalHealth

Our in-silico drug repositioning platform moves beyond narrow-scope tasks. We integrate multimodal biological data – from omics to phenotypes – to capture the complexity of disease biology at a systems level.
Learn more about how we’re changing the game in drug repurposing: delta4.ai/development-...

explore the toolkit: www.theisn.org/wp-content/u...

🔎 A New ISN ADPKD Toolkit standardizes diagnosis & risk assessment. At Delta4, we complement this with in-silico drug discovery, mapping disease mechanisms, prioritizing compounds & biomarkers to speed up effective therapies. #ADPKD #Nephrology #DrugDiscovery

The future of neurodegeneration research is here 🔍

Today, September 30th, join us and Concept Life Sciences for a webinar on:
"Uniting biology and digital drug discovery to identify new therapeutic opportunities in neurodegeneration".

👉 Register now and join the discussion: lnkd.in/ePUadeBE

💙 World Heart Day 2025

Repositioned drugs like SGLT2i, GLP1RAs, MRAs & ERAs show strong cardiorenal benefits. At Delta4, we advance this field with computational & biological insights. Read our Proteomics viewpoint:
analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/...

Towards Molecular and Imaging-Guided Personalized Precision Intervention in Prostate Cancer Prostate Cancer is the most common malignancy affecting men worldwide, characterized by extensive heterogeneity. Almost 45% of prostate cancer patients ...

Submit here: link.springer.com/collections/...

📢 Call for Papers!

Springer Nature launches a collection on molecular & imaging-guided precision intervention in #prostate #cancer, edited by Harald Mischak.

Submit work on biomarkers, AI-driven imaging, or targeted therapies. 🔗 link.springer.com/.

#CallForPapers

YouTube video by FFG Forschung Wirkt. Delta4 - Internationale Netzwerke aufbauen, exzellente Nachwuchstalente gewinnen! #successstory

📹 Proud to see our partner @delta4ai.bsky.social featured by the FFG!

From drug discovery to personalised kidney care, support + science are driving real impact in the PICKED project.

🎥 Watch here: www.youtube.com/watch?v=Tswy...

#PICKEDproject #CKD #MSCA #HorizonEU #DrugDiscovery

🧠 World Alzheimer’s Day 2025

This day reminds us of the complexity of Alzheimer’s disease and the need to better understand the brain’s immune and support cells. Astrocytes are now seen as central players—join our Sept 30 webinar with Concept Life Sciences to learn more.

🚀 Our collaboration with Concept Life Sciences highlights new treatment avenues by targeting astrocytes.

Join us on Sept 30th to see how we combine neuroscience expertise with Delta4’s Hyper-C platform to identify novel targets in neurodegeneration!

📅 Register here: tinyurl.com/CNSwebinar25

🩸 World Sepsis Day 2025 | In sepsis care every moment counts to change and save lives.

We recognize that the fight against sepsis transcends acute care and is about leveraging innovation in computational research to deliver therapies faster, more safely, and tailored to patient needs.

PROMOTE is a cutting-edge EU project shaping the future of prostate cancer detection and treatment.

🎓 Meet Louiza, who is investigating synthetic lethality - targeting gene interactions that selectively kill cancer cells.

Stay tuned as we share further insights from this exciting collaboration!

Last week, the Delta4 team swapped laptops for lawn chairs and data for delicious BBQ at Paul’s garden 🌿🔥

It was the perfect chance to step away from our projects, enjoy good food, and spend some quality time together outside the office. Team spirit is well paired with sunshine! 🥂

🚀 From poster to webinar: the story continues!

In our joint work with Concept Life Sciences, we will be hosting a webinar on September 30th where we’ll explore how computation and biology can unlock new targets in neuroinflammation.

👉 insidescientific.com/webinar/unit...

🟢 September 4 – PKD Awareness Day

🧪 At Delta4, our in-silico drug discovery platform is being applied to uncover existing compounds applicable for ADPKD.

Let’s amplify the voices of those affected and support continued research into this challenging condition!

#ADPKD

🔬 Hyper-C is redefining discovery!

💡 Using AI-supported molecular modeling, it connects compounds to diseases with speed and precision, turning big data into big results. 🚀

Learn more about it: 👉 delta4.ai/hyper-c/

#Delta4 #HyperC

#DisCo-I (Disease Complexity in Fibrosis) is investigating the molecular mechanisms of fibrosis in three major chronic diseases: chronic kidney disease, heart failure, and liver disease.

Find out more about the project: www.disco-1.eu
Learn how Delta4 contributes to EU projects: delta4.ai/picked/

We are thrilled to share that Delta4 is now featured in the Signals Directory, curated by Tim Fitzpatrick, founder of #Signals From [Space] - a growing platform spotlighting ideas, innovations, and investments in kidney health.

Explore the full directory: directory.signalsfs.com/

#KidneyHealth

🧬 #ADPKD is the most common genetically caused kidney disease. Diagnosis is complex, but crucial.
We’ve mapped the diagnostic journey, highlighting key decision tools like imaging and genetic testing. Molecular modeling & AI drug screening may pave the way for potential new therapies.
#KidneyHealth